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Abstract
Background: Artemisinin combination therapies (ACT), which are increasingly being introduced
for treatment of Plasmodium falciparum malaria, are more effective against sexual stage parasites
(gametocytes) than previous first-line antimalarials and therefore have the potential to reduce
parasite transmission. The size of this effect is estimated in symptomatic P. falciparum infections.
Methods: Data on 3,174 patients were pooled from six antimalarial trials conducted in The
Gambia and Kenya. Multivariable regression was used to investigate the role of ACT versus non-
artemisinin antimalarial treatment, treatment failure, presence of pre-treatment gametocytes and
submicroscopic gametocytaemia on transmission to mosquitoes and the area under the curve
(AUC) of gametocyte density during the 28 days of follow up.
Results: ACT treatment was associated with a significant reduction in the probability of being
gametocytaemic on the day of transmission experiments (OR 0.20 95% CI 0.16–0.26), transmission
to mosquitoes by slide-positive gametocyte carriers (OR mosquito infection 0.49 95% CI 0.33–
0.73) and AUC of gametocyte density (ratio of means 0.35 95% CI 0.31–0.41). Parasitological
treatment failure did not account for the difference between ACT and non-artemisinin impact. The
presence of slide-positive gametocytaemia prior to treatment significantly reduced ACT impact on
gametocytaemia (p < 0.001). Taking account of submicroscopic gametocytaemia reduced estimates
of ACT impact in a high transmission setting in Kenya, but not in a lower transmission setting in
the Gambia.
Conclusion: Treatment with ACT significantly reduces infectiousness of individual patients with
uncomplicated falciparum malaria compared to previous first line treatments. Rapid treatment of
cases before gametocytaemia is well developed may enhance the impact of ACT on transmission.
Background
With resistance to chloroquine and sulphadoxine-
pyrimethamine well-established in many malaria
endemic countries, artemisinin combination therapies
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(ACT) are now being introduced for first line treatment of
Plasmodium falciparum malaria [1,2]. Clinical trials of ACT
demonstrate high efficacy [3] and no stable, naturally-
occurring resistance has yet been reported. A potential fur-
ther benefit is that the artemisinin derivative component
of ACT has strong activity against gametocytes, the life
stage of the parasite which is transmitted from humans to
mosquitoes, at all but the most mature stages of their
development [4-6]. This contrasts with previous first line
treatments such as chloroquine and sulphadoxine-
pyrimethmine, which had only limited activity against
early developing gametocytes [7,8]. Furthermore ACT
reduce the asexual parasite population, the source of new
gametocytes, more swiftly [3]. By reducing the infectious-
ness of treated, symptomatic patients, ACT may be used to
reduce overall transmission intensity [9-12] and the
spread of parasite strains resistant to the drug combined
with the artemisinin derivative [13,14]. To assess the
potential for these population level effects, it is important
to have an accurate estimate of the size of ACT impact on
the infectivity of individual, symptomatic P. falciparum
infections.
Previous summary analyses of randomized ACT trials
have shown a reduction in gametocyte prevalence at sin-
gle timepoints during follow up but have focussed on
clinical efficacy [6,15]. Gametocyte density is important
because it is correlated with transmission success to mos-
quitoes, although this relationship is variable [16]. The
best measures of transmission are the proportion of mos-
quitoes infected by feeding on a patient blood sample
[16-18], and the density of infection in those mosquitoes
[16-18]. Here a pooled analysis of six trials is presented,
comparing a range of ACT and non-artemisinin antima-
larials with the focus on obtaining estimates of impact on
gametocyte density over time and on infectivity of
patients to mosquitoes. This includes to the best knowl-
edge of the authors all published studies of mosquito
infection by patients treated with ACT. The roles of treat-
ment failure and pre-treatment gametocytaemia are inves-
tigated as these two factors are expected to influence the
size of ACT impact on transmission as they are rolled out
in malaria-endemic regions.
Methods
Data
Raw data were pooled from six previously published ran-
domized antimalarial trials in which participants were
assessed for infectivity to mosquitoes after treatment
(Table 1) [13,19-22]. Five of the trials were carried out in
Table 1: Baseline characteristics by treatment group and study at day 0. Means are arithmetic. CQ = chloroquine, SP = sulphadoxine-
pyrimethamine, AS1 = 1-dose artesunate, AS-3 = 3-dose artesunate, AL = artemether-lumefantrine (Coartem), AQ = amodiaquine.
Study &
country
Treatment N
Parasitology follow
up days (bold =
transmission
experiment)
Mean age (years)
Mean 
asexual
parasite
density/μl
Mean slide-
positive
gametocyte
prevalence (%)
Mean 
gametocyte
density/μl
1. Gambia Targett 2001 [22] CQ 135 4, 7,14,28 5.9 80,886 2.5 33
SP 277 6.0 73,742 5.6 13
SP-AS1 113 6.2 23,147 10.7 10
SP-AS3 74 6.3 26,567 13.4 88
all 599 6.0 59,581 6.9 26
2. Gambia Targett 2001 [22] SP 101 7,14 4.4 28,684 6.0 31
SP-AS3 404 4.8 27,738 8.0 127
all 505 4.7 27,927 7.6 107
3. Gambia Drakeley 2004 [20] CQ 129 3, 7,14,28 4.7 64,329 20.2 10
CQ-AS 386 4.8 66,593 20.2 22
all 515 4.8 66,026 20.2 19
4. Gambia Hallett 2006 [13] CQ 125 3, 7, 10, 14,28 4.5 63,640 21.6 30
SP 180 4.5 58,128 23.2 47
CQ-SP 193 4.6 79,900 19.2 37
all 498 4.6 68,009 21.2 39
5. Gambia Sutherland 2005 [21] CQ-SP 89 7,14,28 4.3 56,444 4.5 5
AL 400 4.4 57,550 6.3 9
(Coartem)
all 489 4.3 57,347 6.0 9
6. Kenya Bousema 2006 [19] SP 152 3,7, 14,28 3.4 19,044 20.9 7
SP-AQ 127 2.9 20,578 22.3 8
SP-AS3 174 3.2 21,620 24.4 8
AL (Coartem) 75 4.0 21,178 24.6 6
all 528 3.3 20,565 22.9 7Malaria Journal 2008, 7:125 http://www.malariajournal.com/content/7/1/125
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the Gambia during the four month season of intense
transmission (September – December, entomological
inoculation rate (EIR) ~3–50 infectious bites per person
per year (ibppy) [23]) over five successive years (1998–
2002) and one in Kenya in an area of high, perennial
transmission during 2003–2004 (EIR ~70 ibppy). The tri-
als were approved by the relevant ethics committees: the
Joint Gambia Government/Medical Research Council
[13,20-22], the London School of Tropical Medicine and
Hygiene [13,20,21], and the Kenya Medical Research
Institute/National Ethical Review Committee [19], and
complied with the revised Helsinki Declaration of 1983.
The study design and laboratory methods for each trial are
described in detail elsewhere [19-22,24]. In brief, in each
trial patients with uncomplicated microscopy-confirmed
P. falciparum malaria with >500 asexual parasites/μl who
sought treatment at a health centre were randomized to
treatment groups. Altogether four non-artemisinin anti-
malarial regimens were tested: chloroquine (CQ), sul-
phadoxine-pyrimethamine (SP), CQ-SP, sulphadoxine-
pyrimethamine-amodiaquine (SP-AQ) and four ACT:
chloroquine-artesunate (CQ-AS), SP-AS1 (single dose of
artesunate), SP-AS3 (3 days artesunate) and artemether-
lumefantrine (AL). Dosage schedules were as follows:
study 1: CQ: 10 mg/kg days 0–3, SP: 250 mg sulphadox-
ine +12.5 mg pyrimethamine if ≤ 10 kg, plus 125 mg sul-
phadoxine + 6.25 mg pyrimethamine per 5 kg increase in
bodyweight day 0, SP-AS1: as SP, plus 4 mg/kg AS day 0,
SP-AS3: as SP, plus 4 mg/kg AS days 0–2; study 2: SP & SP-
AS3: as study 1; study 3: CQ: 10 mg/kg days 0–1, 5 mg/kg
day 2, CQ-AS: as CQ, plus 4 mg/kg AS days 0–2; study 4:
CQ: as study 3, SP: 25 mg/kg sulphadoxine, 1.25 mg/kg
pyrimethamine day 0, CQ-SP: as CQ & SP; study 5: CQ-
SP: CQ as study 1 days 0–2 plus SP day 0 as study 1, AL:
20 mg artemether plus 120 mg lumefantrine per 5 kg
body weight up to 24 kg, or 120 mg artemether plus 720
mg lumefantrine for 25 kg+ 0 h, 8 h, 20 h, 32 h, 44 h, 56
h; study 6: SP: as study 4, SP-AQ: as SP plus 10 mg/kg AQ
days 0–2, SP-AS3: as SP plus 4 mg/kg AS days 0–2, AL: as
study 5.
Giemsa-stained blood sample smears were made on a
number of days during follow-up until day 14 or day 28
after treatment (Table 1). Presence and density of asexual
parasites and gametocytes were assessed separately in 100
high-powered microscopy fields assuming 1 parasite per
high-powered field is equivalent to 500 parasites/μl (stud-
ies 1–5), or against white blood cells (WBCs), assuming
8000 WBCs/μl (study 6). In study 6, a more sensitive
molecular technique (RNA-based real-time nucleic acid
sequence-based amplication technique (QT-NASBA)
[25]) was used in addition to microscopy. Parasitological
treatment failure was defined as any slide positive for
asexual parasites from day 7 onwards, or an asexual para-
site density on day 3 or 4 which was 10% or more of the
density on day 0. Individuals in study 2, where the follow
up was only 14 days, and those with any missing follow
up parasitology data were excluded from analyses involv-
ing treatment failure. In addition, clinical failure data was
available for 3 studies (3, 5 & 6), defined as patients who
had parasitaemia and a fever (axillary temperature ≥
37°C) at any time during follow up.
Venous blood samples for human-to-mosquito transmis-
sion experiments were taken on a specified day of follow-
up (either 4, 7, 10 or 14, Table 1) from patients who were
slide-positive for gametocytes by Field's stain (all studies).
An additional group of randomly-selected patients
donated blood for transmission experiments regardless of
gametocyte carriage in studies 5 & 6 only. Membrane-
feeding of Anopheles gambiae was performed as previously
described [19-22,24]. In brief, blood samples were centri-
fuged and the red blood cell pellet was resuspended in the
patient's own (autologous) plasma and separately in con-
trol serum from malaria-naïve volunteers in studies 1–5.
In study 6 blood samples were used without further prep-
aration. Female Anopheles gambiae, who were either the F1
progeny of wild-caught gravid females (Studies 1–4), or
from a laboratory colony (studies 5 & 6), were fed on
blood samples through an artificial membrane at 37°C.
Mosquito midguts were dissected at 7–8 days and the
number of oocysts in the mosquito midgut was deter-
mined by microscopy.
Statistical methods
Four outcomes were considered: 1) the area under the
gametocyte density-time curve (AUC), 2) the proportion
of patients with slide-positive gametocytaemia on the day
of mosquito feeding, 3) the proportion of mosquitoes
infected with oocysts (the most readily quantifiable para-
site stage in the mosquito), and 4) oocyst density in each
dissected mosquito midgut. Asexual parasite and gameto-
cyte densities are reported as arithmetic rather than geo-
metric means to take into account zero values and the
variability of the data. The AUC for each individual was
calculated by taking the arithmetic mean of adjacent time-
points and multiplying by the intervening number of
days, using data from days 0, 7, 14 and 28. Individuals
missing gametocyte density readings on day 0, day 28, or
at more than one other timepoint were not included in
the AUC analysis.
Individual treatments were grouped into ACT and non-
artemisinin antimalarials. One treatment regimen which
contained only 1 dose of an artemisinin derivative (SP-
AS1, study 1) was grouped separately. Antimalarials
which were used in at least two studies were also exam-
ined individually; for the remainder, treatment effect
could not be well distinguished from study effect. Game-Malaria Journal 2008, 7:125 http://www.malariajournal.com/content/7/1/125
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tocyte prevalence at day 0 and parasitological treatment
failure were investigated as modifiers of ACT effect on all
four outcomes.
The impact of ACT and other covariates on the AUC (out-
come 1) was analyzed using negative binomial regression,
which models the log of the arithmetic mean and gives a
good fit to the skewed distribution [26]. Regression coef-
ficients can be interpreted as ratios of arithmetic means. A
term was included for random study effects. Densities of
zero were included. The proportion of patients with slide-
positive gametocytaemia on the day of mosquito feeding
(outcome 2) was analysed by logistic regression of patient
level data with random study effects. Finally, multilevel
logistic regression at the mosquito level incorporating
patient and study random effects was used to analyse the
effect of ACT and other covariates on the presence of infec-
tion in the mosquito (outcome 3) and the presence of a
high density oocyst infection, defined as greater than the
median of positive oocyst counts (>4, outcome 4). Mos-
quito-level outcomes could not be adjusted for baseline
factors because the majority of transmission experiments
included only patients who were gametocyte positive at
the time of feeding. Any baseline factors influencing trans-
mission to mosquitoes also influence gametocytaemia
and so inclusion into the dataset. The analysis was there-
fore adjusted only for the type of serum used (autologous
versus control).
All analyses were undertaken using Stata (version 9.2,
StataCorp LP).
Results
Data were available on 3,174 patients in the six trials, of
whom 529 contributed data to the human-to-mosquito
transmission results (Figure 1). Baseline age, asexual par-
asitaemia, gametocytaemia and numbers of mosquitoes
fed per person were significantly different between the
studies (p < 0.05), but treatment groups within studies
were comparable (Table 1). Eighty six participants,
(2.7%) were estimated to have >500 asexual parasites/μl
on the initial Field's-stained slide but were subsequently
found to fail this inclusion criterion after examination of
the confirmatory Giemsa-stained slide. 111 (27.1%)
gametocyte donors for transmission experiments similarly
fit the criterion of gametocyte slide-positivity by the
Field's-stained slide only. Those with zero or missing asex-
ual parasitaemia on day 0 were excluded (n = 76), but the
remainder were retained in the analysis.
Gametocytaemia during follow-up and transmission to 
mosquitoes
Outcomes are shown by study and treatment group in
Table 2 and the pooled analysis is shown in Table 3.
Antimalarial treatment
Compared to non-artemisinin antimalarials, ACT signifi-
cantly reduced the gametocyte AUC during follow up
(ratio of means 0.35 95% CI 0.31–0.41, Figure 2a), game-
tocyte prevalence on day of feeding (OR 0.20 95% CI
0.16–0.26), and transmission to mosquitoes by slide-pos-
itive gametocyte carriers (OR mosquito infection 0.49
95% CI 0.33–0.73). The prevalence of high density oocyst
infections was also reduced although this was not statisti-
cally significant (Table 3). Adjusting the first two out-
comes for baseline asexual parasite density, gametocyte
density, age group, month of transmission season and
parasitological treatment failure did not substantially
change the estimates (ratio of AUC means 0.38 95% CI
0.32–0.47, gametocytes on feed day OR 0.15 95% CI
0.12–0.19) (results of human-to-mosquito transmission
experiments were not adjusted for these factors – see
methods). The lower gametocytaemia in ACT-treated
patients was consistent across studies whereas there was
some variability in the proportions of mosquitoes
infected and oocyst densities (Table 2). These outcomes
were heavily skewed and strongly influenced by small
numbers of highly infectious individuals in each treat-
ment group.
The reduction in arithmetic mean gametocyte density in
the ACT group compared to the non-artemisinin group
varied over time during follow-up (Figure 2), being most
marked up to day 7 and returning to non-significance by
day 28. The same pattern was observed when the analysis
was restricted to slide-positive gametocyte carriers at each
time point i.e. those who could have been selected if a
transmission experiment had been carried out then.
Individual treatment regimens varied in their impact on
transmission outcomes. Compared to CQ, individuals
treated with SP had significantly higher gametocytaemia
during follow up, but slide-positive gametocyte carriers
were less infectious to mosquitoes (Table 3). CQ-SP had a
similar impact to CQ but was more effective at reducing
high oocyst densities. All ACT treatment groups showed
reduced gametocytaemia and lower prevalence of infec-
tion among mosquitoes compared to any non-artemisi-
nin group. This was not seen with respect to oocyst
densities. Within the individual trials however, only the
SP-AS3 group in study 1 did not show reduced oocyst den-
sity (Table 2) compared to the non-artemisinins tested in
the same trial. The artemether-lumefantrine (AL) regimen
which contained 6 doses of artemisinin derivative had a
significantly greater impact on gametocytaemia compared
to the 3-dose regimens CQ-AS and SP-AS (prevalence at
day of feeding: p = 0.001 and overall AUC: p < 0.001,
respectively) and was associated with lower transmission
to mosquitoes although this was not statistically signifi-
cant (p = 0.460) (Table 3). Detectable asexual parasitae-Malaria Journal 2008, 7:125 http://www.malariajournal.com/content/7/1/125
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Overview of trial process and pooled data from the six studies Figure 1
Overview of trial process and pooled data from the six studies.
Clinic patients with diagnosis
of uncomplicated malaria
randomised n=3174
Non-ACT antimalarial: n=1504 ACT: n=1626
Parasitology day 3 (studies 3,4,6)
or day 4 (study 1) : n=1954
Parasitology day 7 (all studies):
n=2496
Parasitology day 14 (all studies):
n=2044
Parasitology day 28
(studies 1,3-6): n=2496
Total human-to-mosquito transmission experiments
n=529 patients
n=18803 mosquitoes fed
96 out of 145 gametocyte carriers
(study 1)
194 out of 633 gametocyte
carriers (studies 1-5), 35 out of all
402 study participants randomly
selected (study 5)
120 out of 401 gametocyte
carriers (studies 1,4,6), 100* of all
473 study participants randomly
selected (study 6)
76 with no or missing
asexual parasitaemia
excluded from analysis
Parasitology day 0 (all studies):
n= 3058
*16 randomly selected patients were also slide-positive gametocyte carriers
Included in human-to-mosquito
transmission experiments
Clinic patients with diagnosis
of uncomplicated malaria
randomised n=3174
Non-ACT antimalarial: n=1504 ACT: n=1626
Parasitology day 3 (studies 3,4,6)
or day 4 (study 1) : n=1954
Parasitology day 7 (all studies):
n=2496
Parasitology day 14 (all studies):
n=2044
Parasitology day 28
(studies 1,3-6): n=2496
Total human-to-mosquito transmission experiments
n=529 patients
n=18803 mosquitoes fed
96 out of 145 gametocyte carriers
(study 1)
194 out of 633 gametocyte
carriers (studies 1-5), 35 out of all
402 study participants randomly
selected (study 5)
120 out of 401 gametocyte
carriers (studies 1,4,6), 100* of all
473 study participants randomly
selected (study 6)
76 with no or missing
asexual parasitaemia
excluded from analysis
Parasitology day 0 (all studies):
n= 3058
*16 randomly selected patients were also slide-positive gametocyte carriers
Included in human-to-mosquito
transmission experimentsMalaria Journal 2008, 7:125 http://www.malariajournal.com/content/7/1/125
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mia was also cleared more quickly in ACT-treated
patients: 3% had positive slides on day 3 compared to
22% among those treated with non-artemisinin (p <
0.001).
Treatment failure
Parasitological failure by day 28 was more common
among those receiving non-artemisinin treatment (42%)
compared to ACT-treated individuals (28%, Table 2).
However, this did not account for any of the impact of
ACT on transmission outcomes, which remained very
similar when parasitological failures were excluded: ratio
of gametocyte AUC means = 0.31 (95% CI 0.25–0.37)
(Figure 2b), OR gametocyte prevalence on the day of feed-
ing = 0.28 (95% CI 0.20–0.38), OR of mosquito infection
by slide-positive gametocyte carriers = 0.46 (95% CI 0.28–
0.76) and OR of high oocyst density 0.49 (0.07–3.62)
(Figure 3a). This may be because parasitological failure
often occurred late in follow-up; 21% of failures were
detected at day 14, and 51% at day 28. These individuals
may have been more infectious at later timepoints than
those contributing to transmission experiments. In the
studies where clinical failure was measured (3, 5 & 6),
only 26% of parasitological failures (91/354) developed
clinical symptoms (42% in the non-artemisinin group
and 16% in the ACT group).
Pre-treatment gametocytes
Slide-positive gametocytaemia on day 0, indicating the
presence of mature gametocytes before treatment, was
predictive of higher gametocytaemia during follow up.
ACT impact on gametocytaemia was reduced among
those with pre-treatment gametocytes (ratio of gameto-
cyte AUC means 0.80 (95% CI 0.64–1.00) and OR of
gametocyte prevalence on the day of feeding 0.41 (95% CI
0.25–0.67) compared to those negative for pre-treatment
Table 2: Gametocytaemia and mosquito level outcomes by treatment group and study. 
Study & country Treatment
Parasitological
treatment
failure (%)
Mean
AUC
per day
% gametocyte
slide-positive
at transmission
experiment
N transmission
experiments
(patients)
% 
mosquitoes
infected*
Mean
oocyst 
density
1. Gambia Targett 2001 [22] CQ 59.3 67.4 17.4 21 13.4 3.1
SP 12.9 117.6 37.8 57 5.5 0.5
SP-AS1 3.8 3.4 16.3 22 8.7 0.5
SP-AS3 0 11.9 25.4 12 18.8 5.2
all 23.9 66.2 27.6 112 9.0 1.6
2. Gambia Targett 2001 [22] SP -† -† 64.0 20 10.7 1.5
SP-AS3 13.4 20 6.1 0.3
all 23.3 40 8.4 0.9
3. Gambia Drakeley 2004 [20] CQ 73.5 58.7 49.5 35 13.1 3.9
CQ-AS 54.7 36.4 26.5 32 5.2 0.4
all 59.6 42.0 32.1 67 9.3 2.1
4. Gambia Hallett 2006 [13] CQ 73.5 81.1 54.2 17 5.5 0.8
SP 57.4 216.2 89.6 30 2.7 0.2
CQ-SP 19.4 134.8 61.3 20 4.6 1.1
all 46.0 147.7 64.8 67 4.0 0.6
5. Gambia Sutherland 2005 [21] CQ-SP 19.0 44.6 41.7 22 3.0 0.1
AL 15.0 2.9 5.8 39 0.1 0.0
(Coartem)
all 15.7 9.9 12.2 61 1.2 0.1
6. Kenya Bousema 2006 [19] SP 54.1 19.2 37.2 71 7.0 -‡
SP-AQ 13.4 11.2 31.6 41 4.7
SP-AS3 17.9 3.9 9.6 41 2.6
AL 4.1 2.3 6.8 29 4.1
(Coartem)
all 25 9.1 21.7 182 5.0
Means are arithmetic. CQ = chloroquine, SP = sulphadoxine-pyrimethamine, AS1 = 1-dose artesunate, AS-3 = 3-dose artesunate, AL = artemether-
lumefantrine (Coartem), AQ = amodiaquine. AUC = area under the gametocyte density-time curve. For numbers of patients contributing to 
parasitology outcomes see Table 1.
* mean of percentages per patient
† follow up was only 14 days compared to 28 days in the other studies. Therefore study 2 was not included in analyses involving parasitological 
failure or the AUC
‡ Oocyst count data was not collectedMalaria Journal 2008, 7:125 http://www.malariajournal.com/content/7/1/125
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Table 3: Treatment effect on four transmission outcomes:
Patient-level outcomes (gametocytaemia)
Variable N patients
Univariate AUC
Ratio
of arithmetic
means (95% CI)
P value N patients
Univariate OR slide-
positive gametocytaemia on
day of feeding
(95% CI)
P value
Antimalarial
CQ (non-artemisinin) 240 1 <0.00 337 1 <0.00
SP (non-artemisinin) 325 1.56 (1.27–1.93) 1 520 3.11 (2.19–4.40) 1
CQ-SP (non-artemisinin) 198 1.03 (0.81–1.32) 227 1.33 (0.86–2.06)
CQ-AS (ACT) 291 0.72 (0.57–0.91) 344 0.42 (0.28–0.62)
SP-AS3 (ACT) 187 0.62 (0.47–0.83) 581 0.50 (0.32–0.78)
AL (Coartem) (ACT) 407 0.18 (0.13–0.25) 404 0.15 (0.08–0.29)
ACT
non-artemisinin 872 1 <0.00 1201 1 <0.00
ACT 885 0.35 (0.31–0.41) 1 1329 0.20 (0.16–0.26) 1
ACT by pre-treatment 
gametocytaemia
day 0 slide-negative ††
non-artemisinin 727 1 <0.00 994 1 <0.00
ACT 745 0.23 (0.19–0.28) 1 1125 0.13 (0.10–0.17) 1
day 0 slide-positive
non-artemisinin 145 1 0.054 164 1
ACT 140 0.80 (0.64–1.00) 183 0.41 (0.25–0.67) <0.00
ACT by parasitological 
treatment failure
No failure †
non-artemisinin 459 1 <0.00 468 1 <0.00
ACT 605 0.31 (0.25–0.37) 615 0.28 (0.20–0.38) 1
Failure 1
non-artemisinin 269 1 <0.00 303 <0.00
ACT 218 0.51 (0.40–0.65) 1 233 0.33 (0.22–0.49) 1
Mosquito-level outcomes
Variable N mosquito es Adjusted OR mosquito 
infection (95% CI)*
P value N mosquito es Adjusted OR oocyst count per 
midgut in highest 50% of positive 
counts (4) (95% CI)*
P value
Antimalarial
CQ (non-artemisinin) 2194 1 0.002 2194 1 <0.00
SP (non-artemisinin) 6762 0.42 (0.20–0.87) 4079 0.25 (0.09–0.75) 1
CQ-SP (non-artemisinin) 1277 1.28 (0.43–3.85) 1146 0.12 (0.03–0.58)
CQ-AS (ACT) 974 0.28 (0.11–0.71) 974 0.25 (0.05–1.21)
SP-AS3 (ACT) 2793 0.29 (0.12–0.69) 1439 0.39 (0.09–1.8)
AL (Coartem) (ACT) 2299 0.22 (0.08–0.61) 292 - ‡
ACT
non-artemisinin 11653 1 0.029 7419 1 0.165
ACT 6066 0.49 (0.33–0.73) 2705 0.45 (0.14–1.39)
ACT by pre-treatment 
gametocytaemia
day 0 slide-negative
non-artemisinin 8811 1 0.002 5700 1 0.008
ACT 4039 0.49 (0.31–0.77) 1419 0.11 (0.02–0.56)Malaria Journal 2008, 7:125 http://www.malariajournal.com/content/7/1/125
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gametocytes (ratio of gametocyte AUC means 0.23 (95%
CI 0.19–0.28) and OR of gametocyte prevalence on the
day of feeding 0.13 (95% CI 0.10–0.17) (interaction p <
0.001 for both outcomes) (Figure 2c). The pattern was
similar for the oocyst density outcome, although the dif-
ference between the effects of the ACT and non-artemisi-
nin groups was not significant (Figure 3b, Table 3). ACT
impact on transmission to mosquitoes by slide-positive
gametocyte carriers was similar among those with and
without pre-treatment gametocytes (Table 3).
Submicroscopic gametocytaemia
In study 6, the molecular QT-NASBA technique detected
gametocytes in 311/332 (94%) of blood samples that
were classified gametocyte-positive by microscopy, and
furthermore in 615/959 (64%) of those classified nega-
tive, giving a higher estimated prevalence of gametocytes
at all timepoints [19]. Gametocyte density readings
matched poorly between the two techniques so preva-
lence data is used to compare them.
Among patients who were tested by both QT-NASBA and
microscopy (n = 249), ACT impact on gametocytaemia
was smaller if submicroscopic gametocyte carriers were
taken into account. The ratio of means of the area under
the gametocyte prevalence-time curve comparing ACT to
non-artemisinin antimalarials was 0.40 (95% CI 0.23–
0.69 p < 0.001) using microscopy data, compared to 0.60
(95% CI 0.51–0.70 p < 0.001) with QT-NASBA data. This
difference suggests bias is introduced by microscopy
because a greater proportion of ACT-treated gametocyte
carriers have a density in the submicroscopic range.
In study 5 in The Gambia, 1/1165 (0.1%) mosquitoes
were infected when feeds were performed on 33 individu-
als who were gametocyte slide-negative, compared to 19/
882 (2.2%) mosquitoes who were infected by 26 gameto-
cyte carriers in the same study. This suggests that infection
of mosquitoes by submicroscopic gametocytaemia was
rare in this setting. By contrast, gametocyte slide-negative
individuals in study 6 in Kenya infected almost as high a
proportion of mosquitoes as gametocyte slide-positive
patients: 4.7% compared to 5.9%. In this study the impact
of ACT was substantially smaller if "being infectious" was
defined as infecting any mosquitoes (regardless of micro-
scopic gametocytaemia), rather than as being gametocyte
slide-positive on the day of feeding (OR infecting any
mosquitoes at feeding 0.42 95% CI 0.18–0.97 versus OR
gametocyte prevalence at feeding = 0.14 95% CI 0.04–
0.44).
Discussion
These results demonstrate that gametocytaemia among
ACT-treated patients is significantly lower than in individ-
uals treated with non-artemisinin antimalarials during 28
days of follow up. ACT treatment is also associated with
reduced human-to-mosquito transmission both among
those with microscopically detectable gametocytes, and
randomly selected patients. ACT appear to destroy a sub-
stantial proportion of immature, developing gametocytes
while sequestered in the microvasculature, resulting in a
significant reduction in the release of mature gametocytes
into the peripheral blood. Their more rapid reduction of
the asexual reservoir may also contribute.
Transmission to mosquitoes was measured mainly at day
7 when ACT impact on gametocytaemia was at one of its
highest points. Although gametocyte density is not the
only factor determining transmission to mosquitoes
(maturity and sex ratio of gametocytes are also important
[17,27]), the AUC analysis may give an estimate more rep-
resentative of the overall impact during the follow up
day 0 slide-positive
non-artemisinin 2277 1 <0.00 1326 1 0.102
ACT 1870 0.30 (0.16–0.55) 1 1129 0.28 (0.06–1.29)
ACT by parasitological 
treatment failure
No failure
non-artemisinin 4773 1 0.003 2037 1 0.486
ACT 3496 0.46 (0.28–0.76) 740 0.49 (0.07–3.62)
Failure
non-artemisinin 3027 1 0.021 1574 1 0.294
ACT 897 0.37 (0.16–0.86) 572 0.33 (0.04–2.59)
at the patient level, the area under the curve of gametocyte density (microscopy measurement) during follow up (28 days), the presence of slide-
positive gametocytaemia on the day of feeding; at the mosquito level, the presence of infection in mosquitoes, and high density infection in 
mosquitoes.
* adjusted for type of serum (autologous/control) used in transmission experiment
† P interaction with ACT/non-artemisinin <0.05
‡ Mosquitoes were infected only in study 6 where oocyst data was not collected, except one mosquito in study 5 which had a missing oocyst count.
Table 3: Treatment effect on four transmission outcomes: (Continued)Malaria Journal 2008, 7:125 http://www.malariajournal.com/content/7/1/125
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Mean gametocyte density/μl during follow up in ACT (black, circles) and non-artemisinin (grey, triangles) antimalarial treatment  groups, pooled results from the six trials (a) overall (b) stratified by parasitological treatment failure (c) stratified by presence  of pre-treatment gametocytes Figure 2
Mean gametocyte density/μl during follow up in ACT (black, circles) and non-artemisinin (grey, triangles) anti-
malarial treatment groups, pooled results from the six trials (a) overall (b) stratified by parasitological treat-
ment failure (c) stratified by presence of pre-treatment gametocytes. Error bars show 95% confidence intervals. 
Lines drawn in between data points are theoretical only. Below: ratios showing ACT impact on gametocyte prevalence and 
density on each follow up day, allowing for random study effects.
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Box plots showing oocyst densities by ACT and (a) parasitological treatment failure and (b) pre-treatment gametocytes Figure 3
Box plots showing oocyst densities by ACT and (a) parasitological treatment failure and (b) pre-treatment 
gametocytes.
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period. Longitudinal feeding studies would also be valua-
ble as the infectiousness of gametocytes may change over
the course of an infection [24].
Higher levels of parasitological treatment failure among
non-artemisinin treated individuals did not account for
any of the higher observed ACT impact on gametocytae-
mia and transmission to mosquitoes. However, parasito-
logical failure did predict higher gametocytaemia and
transmission to mosquitoes. Drug resistant parasite geno-
types have been shown to enhance transmission by boost-
ing gametocyte numbers, particularly in patients treated
with monotherapies [13,20]. The late appearance of asex-
ual parasites among treatment failures would mean that
most of the resulting gametocytes would become patent
and transmit after the 28 day follow-up period. Low rates
of clinical symptoms among parasitological failures, at
least during the period of follow up, suggests these indi-
viduals may not receive further treatment and so would
subsequently be important contributors to transmission.
ACT impact was slightly higher among treatment failures
than successes, which may reflect a higher proportion of
new parasite inocula as opposed to recrudescent infec-
tions in the ACT treatment failure group, which had not
yet produced gametocytes [28]. ACT were significantly less
able to reduce gametocytaemia among individuals who
were slide-positive for gametocytes on presentation, prob-
ably because they do not act against mature gametocytes
[5]. The pattern of gametocyte density over time among
these patients was consistent with that of natural decay of
mature gametocytes and limited subsequent release of
developing gametocytes from sequestration. Duration of
symptoms prior to treatment seeking has been shown to
have a strong relationship with gametocyte prevalence at
baseline [29]. Interventions to improve the speed of treat-
ment seeking could therefore enhance the impact of ACT
on transmission. However, older asymptomatic infections
also contribute to the presence of gametocytaemia at base-
line [29] and therefore ACT impact may be reduced in
high transmission settings or towards the end of a period
of seasonal transmission.
Study 6 in Kenya [19] highlighted the importance of sub-
microscopic gametocytaemia in studies of human infec-
tiousness. Taking this into account reduced the estimate
of ACT impact on gametocytaemia and in particular trans-
mission to mosquitoes. However, study 5 in the Gambia
showed little evidence of transmission from submicro-
scopic carriers [21]. The reason for this difference in find-
ings is not clear. Differences in laboratory procedures are
unlikely to be accountable because the infectiousness of
gametocyte slide-positive individuals is comparable
between the studies. The lower intensity of transmission
in the Gambia, and concomitant seasonal fluctuations in
gametocyte carriage are probably important [30]. How-
ever, high levels of submicroscopic gametocytaemia have
been found in other low transmission settings, although
the infectiousness of these individuals was not tested [31].
Further research is needed to determine the relationship
between submicroscopic gametocytaemia, infectivity, and
transmission setting.
The grouping of different treatments into non-artemisinin
and ACT categories in these results is simplistic since indi-
vidual treatment regimens within these groups sometimes
had significantly different associations with the outcomes
(Table 3). Therefore our estimates of ACT effect depend to
some extent on the numbers of patients treated with each
regimen in these studies. Some evidence exists that non-
artemisinin antimalarials stimulate the post-treatment
release of immature gametocytes to different extents
[8,32], although these may not be sufficiently mature to
infect mosquitoes [24], whilst other evidence suggests the
gametocytaemia is no different from what would be
expected in an untreated infection [33,34].
While it is useful to have a pooled estimate of ACT impact
from these studies, the heterogeneity in results should not
be overlooked. The laboratory methods used in each of
the studies were mostly very similar, but there were some
variations which may have influenced the estimated ACT
impact, such as the number of days between treatment
and measurement of human-to-mosquito transmission,
and different microscopists. For example, the SP-AS3
treatment group in study 1 did not show reduced oocyst
density among blood-fed mosquitoes compared to non-
artemisinin treatments, but only 12 patients in this group
participated in feeding experiments. Of the 6 individuals
successfully infecting mosquitoes at day 4, two were
already harbouring gametocytes at day 0, and a third had
very high day 4 gametocytaemia. These individuals almost
certainly carried gametocytes on day 4 representative of a
substantial pre-treatment gametocyte population, and
may have been less infectious if transmission experiments
were performed 7 or 14 days after treatment, as in the
other studies analysed. Differences in baseline characteris-
tics between studies such as transmission setting could
also have caused differences in ACT effects.
These results are representative of ACT effects upon young
symptomatic patients in a trial setting. In order to evaluate
potential impact of ACT on population-level transmis-
sion, it will be crucial to know the proportion of infec-
tions which are asymptomatic and so untreated in
different transmission settings, and their relative contribu-
tion to the infectious reservoir. Many other operational
factors including the coverage of ACT relative to other
antimalarials and levels of adherence to treatment regi-
mens will also be important in determining such effects.
Empirical observations on population gametocyte car-Malaria Journal 2008, 7:125 http://www.malariajournal.com/content/7/1/125
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riage and its evolutionary basis [18,35] will aid this more
comprehensive evaluation. Ongoing monitoring of the
impact of ACT on transmission could be an important
surveillance tool, as the early signs of spreading resistance
to these regimens are likely to be enhanced transmission
from treated individuals [24].
Conclusion
ACT reduce gametocytaemia and onward transmission to
mosquitoes significantly compared to previous first-line
non-artemisinin antimalarials, although transmission
from ACT-treated patients is not fully prevented. Malaria
transmission intensity could potentially be reduced as
ACT are scaled up in malaria-endemic countries, however
it will be important to quantify the proportion of asymp-
tomatic and therefore untreated infections in different
populations. ACT impact is likely to be reduced by factors
which increase the presence of mature gametocytes before
treatment, such as lack of rapid access to treatment or high
malaria transmission intensity. Future studies of different
antimalarials should also measure the infectiousness of
gametocyte carriers with submicroscopic densities, to fur-
ther clarify the contribution of such individuals to post-
treatment transmission.
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